APA (7th ed.) Citation

AC, S., SD, v. H., E, B., Z, S., M, A., A, T., . . . LR, B. (2024). Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series. Vaccine, 42(22), 126054. https://doi.org/10.1016/j.vaccine.2024.05.081

Chicago Style (17th ed.) Citation

AC, Sherman, et al. "Heterologous SARS-CoV-2 Booster Vaccine for Individuals with Hematological Malignancies After a Primary SARS-CoV-2 MRNA Vaccine Series." Vaccine 42, no. 22 (2024): 126054. https://doi.org/10.1016/j.vaccine.2024.05.081.

MLA (9th ed.) Citation

AC, Sherman, et al. "Heterologous SARS-CoV-2 Booster Vaccine for Individuals with Hematological Malignancies After a Primary SARS-CoV-2 MRNA Vaccine Series." Vaccine, vol. 42, no. 22, 2024, p. 126054, https://doi.org/10.1016/j.vaccine.2024.05.081.